NRx Pharmaceuticals (NASDAQ:NRXP) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report published on Thursday morning,Benzinga reports. They currently have a $19.00 price objective on the stock.

Several other analysts have also recently issued reports on the company. D. Boral Capital restated a “buy” rating and set a $31.00 price objective on shares of NRx Pharmaceuticals in a research note on Monday, March 17th. Ascendiant Capital Markets upped their price objective on NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, December 2nd.

NRx Pharmaceuticals Stock Performance

NASDAQ:NRXP opened at $2.08 on Thursday. NRx Pharmaceuticals has a one year low of $1.10 and a one year high of $6.01. The business’s 50-day simple moving average is $2.82 and its 200 day simple moving average is $2.03. The stock has a market cap of $35.19 million, a price-to-earnings ratio of -0.97 and a beta of 1.22.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). On average, equities research analysts predict that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Trading of NRx Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Sassicaia Capital Advisers LLC acquired a new stake in shares of NRx Pharmaceuticals during the 4th quarter worth approximately $33,000. Townsquare Capital LLC acquired a new stake in shares of NRx Pharmaceuticals during the 3rd quarter worth approximately $25,000. Squarepoint Ops LLC acquired a new stake in shares of NRx Pharmaceuticals during the 4th quarter worth approximately $56,000. Millennium Management LLC acquired a new stake in shares of NRx Pharmaceuticals during the 4th quarter worth approximately $61,000. Finally, Anson Funds Management LP raised its position in shares of NRx Pharmaceuticals by 30.3% during the 4th quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock worth $408,000 after purchasing an additional 43,135 shares during the period. 4.27% of the stock is currently owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.